Onconic Therapeutics Expands to Indonesia with Zacubo through Supply Agreement with Dexa Medica
Dexa Medica to Handle Local Approval and Sales,
Onconic to Supply Finished Products
Expanding into the Southeast Asian Market Following China, India, and Mexico
Onconic Therapeutics' gastroesophageal reflux disease (GERD) treatment, Zacubo, is entering the Indonesian market.
On June 11, Onconic Therapeutics announced that it had signed a license and supply agreement for Zacubo (ingredient name: Zastaprazan) with the Indonesian pharmaceutical company Dexa Medica.
Under this agreement, Dexa Medica will be responsible for obtaining product approval and handling sales in Indonesia, while Onconic Therapeutics will supply the finished products. Details such as the scale of the contract have not been disclosed.
Dexa Medica is a local pharmaceutical company with a sales and distribution network across Indonesia. Through its subsidiary, Medela Potentia, it operates a pharmaceutical distribution business and has extensive experience in importing and commercializing various overseas medicines.
Indonesia is considered the largest market in Southeast Asia, with a population of approximately 280 million. The market for gastroesophageal reflux disease treatments continues to show annual growth, and demand for related pharmaceuticals is increasing due to improved medical accessibility and the expansion of health insurance coverage.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Onconic Therapeutics has currently applied for product approval for Zacubo in China and is conducting Phase 3 clinical trials to secure additional indications. Recently, the company has also completed approval applications in India and Mexico, further expanding its entry into overseas markets.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.